TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $297.39 million. The enterprise value is $192.75 million.
| Market Cap | 297.39M |
| Enterprise Value | 192.75M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, before market open.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 43.61 million shares outstanding. The number of shares has increased by 172.78% in one year.
| Shares Outstanding | 43.61M |
| Shares Change (YoY) | +172.78% |
| Shares Change (QoQ) | -30.82% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 83.14% |
| Float | 21.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.13 |
| Forward PS | 17.66 |
| PB Ratio | 1.97 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.51, with a Debt / Equity ratio of 0.61.
| Current Ratio | 6.51 |
| Quick Ratio | n/a |
| Debt / Equity | 0.61 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.73 |
Financial Efficiency
Return on equity (ROE) is -60.60% and return on invested capital (ROIC) is -38.41%.
| Return on Equity (ROE) | -60.60% |
| Return on Assets (ROA) | -33.90% |
| Return on Capital (ROIC) | -38.41% |
| Revenue Per Employee | $136,682 |
| Profits Per Employee | -$579,338 |
| Employee Count | 154 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +201.77% in the last 52 weeks. The beta is 0.90, so TCRX's price volatility has been lower than the market average.
| Beta (1Y) | 0.90 |
| 52-Week Price Change | +201.77% |
| 50-Day Moving Average | 7.00 |
| 200-Day Moving Average | 4.62 |
| Relative Strength Index (RSI) | 43.73 |
| Average Volume (30 Days) | 192,222 |
Short Selling Information
The latest short interest is 219,413, so 0.50% of the outstanding shares have been sold short.
| Short Interest | 219,413 |
| Short Previous Month | 188,336 |
| Short % of Shares Out | 0.50% |
| Short % of Float | 1.04% |
| Short Ratio (days to cover) | 1.05 |
Income Statement
In the last 12 months, TCRX had revenue of $21.05 million and -$89.22 million in losses. Loss per share was -$1.36.
| Revenue | 21.05M |
| Gross Profit | 21.05M |
| Operating Income | -93.46M |
| Pretax Income | -89.22M |
| Net Income | -89.22M |
| EBITDA | -80.10M |
| EBIT | -85.46M |
| Loss Per Share | -$1.36 |
Balance Sheet
The company has $197.08 million in cash and $92.43 million in debt, giving a net cash position of $104.64 million or $2.40 per share.
| Cash & Cash Equivalents | 197.08M |
| Total Debt | 92.43M |
| Net Cash | 104.64M |
| Net Cash Per Share | $2.40 |
| Equity / Book Value | 150.87M |
| Book Value Per Share | 3.46 |
| Working Capital | 164.42M |
Cash Flow
In the last 12 months, operating cash flow was -$61.36 million and capital expenditures -$3.15 million, giving a free cash flow of -$64.50 million.
| Operating Cash Flow | -61.36M |
| Capital Expenditures | -3.15M |
| Free Cash Flow | -64.50M |
| FCF Per Share | -$0.98 |
Margins
Gross margin is 100.00%, with operating and profit margins of -444.00% and -423.86%.
| Gross Margin | 100.00% |
| Operating Margin | -444.00% |
| Pretax Margin | -423.86% |
| Profit Margin | -423.86% |
| EBITDA Margin | -380.53% |
| EBIT Margin | -406.00% |
| FCF Margin | -306.45% |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -172.78% |
| Shareholder Yield | -172.78% |
| Earnings Yield | -30.00% |
| FCF Yield | -21.69% |
Analyst Forecast
The average price target for TCRX is $11.00, which is 61.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 61.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 20.99% |
| EPS Growth Forecast (5Y) | -2.41% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -0.04 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.04 |
| Piotroski F-Score | 2 |